Gavi, the Vaccine Alliance helps vaccinate half the world’s children against deadly and debilitating diseases. #VaccinesWork #ForOurFuture
Gavi
Loading...
In parts of West Africa, Lassa fever and rabies frequently threaten the same communities. In areas with limited healthcare access, every separate vaccine injection is a challenge to deliver.
Gavi
New vaccines to protect against tuberculosis are finally on the horizon, with leading candidates currently in Phase III testing to offer broader protection for adults and adolescents.
Here’s how experts are moving from reactive planning to proactive readiness: bit.ly/4vzxCXG
Outbreaks are rarely contained by vaccines alone. Here’s how communication, community engagement and trust all shape the impact vaccines can have: bit.ly/4oemtZQ via The Conversation
Researchers at the University of Cambridge have successfully used AI to scan sarbecoviruses (the viral family including SARS and COVID), looking for shared genetic features that evolution has left largely untouched.
Most children receive vaccines weeks or months later than recommended, especially in low- and middle-income countries. Yet even a delay of a few weeks can leave them vulnerable during periods when the risk of serious disease is highest.
Here's why vaccine timing matters: bit.ly/4vFJwzt
In the DRC, community health workers are mapping remote villages and traveling long distances to ensure zero-dose children are no longer left behind. For parents, the arrival of these routine mobile clinics brings relief in the face of preventable outbreaks.
The full story: bit.ly/4ei2vJl
With an active Bundibugyo Ebola outbreak in the DRC and Uganda, researchers are working rapidly to move new vaccine candidates into trials.
Here’s a look into the complex scientific and economic race to build a vaccine for Bundibugyo: bit.ly/3SxOeAM via The Conversation
A new combination vaccine candidate for rabies and Lassa fever aims to solve that problem by bundling protection into a single vaccine. If approved, it would be a big step towards streamlining delivery and protecting vulnerable communities against two deadly viral threats at once.
Those shared features became the basis of a new vaccine candidate currently in testing, designed to work against the whole viral family rather than just a single strain.
The full science explainer: bit.ly/4alXIVS via The Conversation
Early results from the first human trials show promising safety profiles and immune responses. The latest: bit.ly/4gbSM9P
